tbuckley/cabot-search huggingface dataset:
BUENOS AIRES
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiology
Authors: James E. Dalen
Journal: JAMA (1986)

During the past several years, there have been dramatic changes in the therapeutic approach to coronary artery disease. Percutaneous transluminal coronary angioplasty (PTCA) and thrombolytic therapy are being increasingly utilized, and the indications for coronary artery bypass grafting are being refined. First used in patients with coronary artery disease (CAD) in 1977, PTCA has gained wide acceptance as an alternative form of myocardial revascularization. Patients with unstable angina, initially considered to be unsuitable candidates for PTCA, have now undergone this procedure, with initial success rates of 93% reported.<sup>1</sup>Multivessel PTCA is now being performed with excellent short-term results and acceptable complication rates. As an extension of PTCA, balloon angioplasty has been successfully used to treat pediatric patients with coarctation of the aorta, pulmonary stenosis, and mitral stenosis. Several centers have used percutaneous balloon valvuloplasty, with promising short-term results, to treat adults with aortic and mitral stenosis.<sup>2</sup> Percutaneous transluminal
Rheumatology
Authors: G. E. Ehrlich
Journal: JAMA (1979)

Four principals occupied center stage in rheumatology during 1978: (1) HLA genetic markers, (2) various new as well as old drugs, (3) the genesis of osteoarthritis, and (4) perhaps the most enigmatic of them all, mixed connective tissue disease. <h3>Genetic Markers</h3> The HLA system of antigens continues to be implicated in the development of some of the rheumatic diseases, even if the guilt is still primarily by association. The best established relationship remains that between the HLA-B27 antigen and ankylosing spondylitis. When spondylitic changes are associated with either acute anterior uveitis or Reiter's syndrome, this strong association remains. However, the distribution of HLA-B27 among persons with nonspecific urethritis is similar to that among healthy control subjects, and, therefore, it is important that the HLA-B27 antigen be related to the joint involvement and not to the urethritis.<sup>1</sup>The frequency of the association of the HLA antigen with the rheumatic diseases
Free Radical Generation by Ultrasound in Aqueous and Nonaqueous Solutions
Authors: P. Riesz, D. Berdahl, C. L. Christman
Journal: Environmental Health Perspectives (1985)

The physical principles underlying the oscillatory behavior of minute gas bubbles in liquids exposed to ultrasound are reviewed. Results from mathematical analyses suggest that these oscillations sometimes become unstable leading to transient cavitation in which a bubble violently collapses during a single acoustic half-cycle producing high temperatures and pressures. The role that micronuclei, resonant bubble size, and rectified diffusion play in the initiation of transient cavitation is explained. Evidence to support these theoretical predictions is presented with particular emphasis on sonoluminescence which provides some non-chemical evidence for the formation of free radicals. Acoustic methods for conducting sonochemical investigations are discussed. In aqueous solutions transient cavitation initially generates hydrogen atoms and hydroxyl radicals which may recombine to form hydrogen and hydrogen peroxide or may react with solutes in the gas phase, at the gas-liquid boundary or in the bulk of the solution. The analogies and differences between sonochemistry and ionizing radiation chemistry are explored. The use of spin trapping and electron spin resonance to identify hydrogen atoms and hydroxyl radicals conclusively and to detect transient cavitation produced by continuous wave and by pulsed ultrasound is described in detail. The study of the chemical effects of cavitation in organic liquids is a relatively unexplored area which has recently become the subject of renewed interest. Examples of the decomposition of solvent and solute, of ultrasonically initiated free-radical polymerization and polymer degradation are presented. Spin trapping has been used to identify radicals in organic liquids, in polymer degradation and in the decomposition of organometallic compounds.
Objective Assessment of Gastroesophageal Reflux Secondary to Hiatal Hernia
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Parainfluenza virus type 3: isolation from CSF of a patient with Guillain-Barre syndrome
Authors: G. Roman
Journal: JAMA (1978)

We report the isolation of parainfluenza virus type 3 from the CSF of a 19-year-old man with Guillain-Barré syndrome. Although parainfluenza viruses are usually associated with respiratory tract illnesses, some strains show a neurotropism not previously appreciated. Thus, parainfluenza viruses may be responsible for a portion of cases of Guillain-Barré syndrome. (<i>JAMA</i>240:1613-1615, 1978)
NOTES ON OPHTHALMIC DISEASES
Authors: J. V. Solomon
Journal: BMJ (1854)

dl&la bo eV fi 17th, onlaing, tea mdX gg danDy increasing the preso over t tr coon, a _eatio was experienced similr to prsg vwy itly en a small bag of auts.On the foUowng mognn, there wa a copious and thin bilious evauai, t the 6dOm of which were found twenty-sven the larget of .ihekwas nearly roud, with sd two and a quarter inche in rc ee weiging dried ninety grains, the specifi gi ty being ebout .750.Te remaning twenty-g s vaed in from that of a large lmond to a small p each with cettes like the largest.On the eveaing of the saye dxty-four more gall-stones were pa in one thin biious evacuation: they varied in size from a horse-bean to a hempseed, and some were firmly adherent by their facettes.This was followed by four hours of refreshing sleep-the first he had had for seven days.One of the gall-stones pre- sented on section various concentric layers, apparently of inpissated bile; there was ne discoverable nucleus or caity; the outside layer was dark brown, but rystline; * Attempts have been frequently made to obtain a supply of purer water by boring, but hitherto without much success; the reults being, waters cuore or lese Impregnated with chloride of sodium.+ A widely difused epidemic Influenoe bas likewise evidently prevailed, ts isolted cases of malarios disease have come under my notic from other ow laevel and as the almost universally provalent asthenic type of disease
Insidious and prolonged antagonism of guanethidine by amitriptyline
Authors: J. F. Meyer
Journal: JAMA (1970)

A hypersensitive, 47-year-old man was adequately treated with guanethidine sulfate, 75 mg/day. Because of depression he was treated with amitriptyline hydrochloride, 25 mg, three times daily, and 300 mg of guanethidine sulfate was required for adequate control. Administration of amitriptyline was discontinued and the patient experienced pronounced orthostatic hypotension with 87.5 mg of guanethidine sulfate daily. After five days of amitriptyline hydrochloride therapy, 150 mg/day, the effects of guanethidine were again eliminated. The hypotensive effect of guanethidine did not return until 18 days after amitriptyline therapy was discontinued.
NCCN NewsNCCN Moves Global Headquarters to Plymouth Meeting, PANavigating Neuroendocrine TumorsNCCN Awarded $2 Million in Research Funding From Taiho Oncology to Study Trifluridine and Tipiracil in Various Cancers
Journal: Journal of the National Comprehensive Cancer Network (2018)

NCCN has moved from Fort Washington, PA, into new headquarters in Plymouth Meeting, PA, near
Test Tubes and Dragon Scales
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pediatrics, Springfield, Illinois
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
5. Prevention or Delay of Type 2 Diabetes: <i>Standards of Medical Care in Diabetes—2018</i>
Journal: Diabetes Care (2017)

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Reply to Mengda Zhang and Long Wang’s Letter to the Editor re: Francesco Porpiglia, Enrico Checcucci, Daniele Amparore, et al. Three-dimensional Augmented Reality Robot-assisted Partial Nephrectomy in Case of Complex Tumours (PADUA ≥ 10): A New Intraoperative Tool Overcoming the Ultrasound Guidance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.11.024
Authors: Daniele Amparore, Enrico Checcucci, Cristian Fiori, Francesco Porpiglia
Journal: European Urology (2020)
Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study
Authors: Peter A. Merkel, Grace H. Lo, Janet T. Holbrook, Andrea K. Tibbs, Nancy B. Allen, John C. Davis, Gary S. Hoffman, W. Joseph McCune, E. William St. Clair, Ulrich Specks, Robert Spiera, Michelle Petri, John H. Stone
Journal: Annals of Internal Medicine (2005)

Background: Venous thrombotic events (VTEs) have been observed in Wegener granulomatosis, but the incidence rate is not known. Objective: To measure the incidence of VTEs in patients with Wegener granulomatosis. Design: Prospective, observational cohort study. Setting: A multicenter, randomized, double-blind, placebo-controlled treatment trial for Wegener granulomatosis. Patients: 180 patients with Wegener granulomatosis enrolled during periods of active disease. Measurements: Venous thrombotic events (deep venous thromboses or pulmonary emboli) were documented and confirmed prospectively. Incidence rates were calculated on the basis of time to first VTE. Results: Thirteen patients had VTEs before enrollment. During 228 person-years of prospective follow-up, 16 VTEs occurred in 167 patients with no history of VTE. Median time from enrollment to VTE for patients with an event was 2.1 months. The incidence of VTE among patients with Wegener granulomatosis was 7.0 per 100 person-years (95% CI, 4.0 to 11.4). Limitations: Although prospectively recorded, screening for VTEs did not occur. Conclusions: The incidence rate of VTEs in Wegener granulomatosis is high when compared with available rates in the general population, patients with lupus, and patients with rheumatoid arthritis. These results have important implications for clinical care of patients with Wegener granulomatosis. *For a list of members of The Wegener's Granulomatosis Etanercept Trial Research Group, see the Appendix.
Abstract 5186: Discovery of a novel histone deacetylase 6 inhibitor that kills drug-resistant breast cancer
Authors: Catríona Dowling, Eugene Dillion, Michael Hemann, Gerard Cagney, Anthony Letai, Triona Ni Chonghaile
Journal: Cancer Research (2019)

Abstract Cytotoxic chemotherapy is the standard of care for patients with triple negative breast cancer (TNBC). Most patients with advanced TNBC progress after chemotherapy and die from metastatic disease. Currently, no established targeted therapeutics or biomarkers of outcome/response have been clinically approved in the context of TNBC. The aggressive nature of TNBC is reflected by an increased likelihood of distant recurrence and death within five years following primary intervention and a shorter survival once diagnosed with metastatic disease. To identify novel therapeutics for the treatment of chemoresistant TNBC, we performed a high-throughput screen to identify small molecules that are cancer selective but can kill drug-resistant TNBC cells. We screened a total of 30,000 compounds in duplicate across the TNBC cell line MDA-MB-321 in which the pro-death proteins BAX/BAK were knocked down, and the non-transformed "normal" MCF10A cell line. There was a hit rate of 0.3% in the screen and 85 compounds were retested in the validation cherry pick screen. From this screen 18 compounds were further validated with low-throughput assessment for mitochondrial independent killing and selectivity for cancer cells. To identify the mechanism of action of the lead compound we used a genetic approach to generate an RNAi signature for the compound, which indicated the lead compound was most likely that of histone deacetylase inhibitor (HDAC). Using an in vitro HDAC inhibitor screen, we identified that the compound specifically inhibited HDAC6. Using a series of cell based assays, we determined that treatment of cells with the compound BAS-2 resulted in the same phenotypical response (inhibition of migration, invasion and 3D spheroid formation) as HDAC6 knockout. To identify substrates of HDAC6 in cells we analyzed the proteome for increased acetylation by mass spectrometry following HDAC6 knockout or inhibition with the specific inhibitor, BAS-2. Remarkably, we identified a series of new substrates for HDAC6 that are common in both the HDAC6 knockdown and BAS-2 treated cells. In conclusion, we have identified a novel HDAC6 specific inhibitor that selectively kills cancer cells independent of mitochondrial apoptosis, alters acetylation of over a 50 common proteins and inhibits spheroid formation of TNBC. Citation Format: Catríona Dowling, Eugene Dillion, Michael Hemann, Gerard Cagney, Anthony Letai, Triona Ni Chonghaile. Discovery of a novel histone deacetylase 6 inhibitor that kills drug-resistant breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5186.
Abstract 214: Tracking of CD16 Monocytes Following Delivery Into the Ischemic Limb - a Bench to Bedside Study
Authors: Ashish S Patel, Francesca E Ludwinski, Alexander Kerr, Jun Cho, Christopher Fisher, Andrew Hope, Lefteris Livieratos, Prakash Saha, Oliver T Lyons, Alberto Smith, Bijan Modarai
Journal: Circulation Research (2017)

Introduction: The poor retention of cells delivered into ischemic tissue is a hurdle that needs to be addressed for cell therapy to be effective. We have previously shown that CD16+ monocytes expressing upregulated cell adhesion markers are mobilized in critical limb ischemia (CLI) and salvage limbs in pre-clinical studies of hindlimb ischemia (HLI). We hypothesized that these cells are well retained following delivery into ischemic muscle. Methods and Results: CD16+ and CD16- monocytes were isolated from CLI patients, fluorescently labeled with QuantumDots and injected into the adductor muscle of nude athymic mice following HLI (n=15/group). Flow cytometric analysis of cell suspensions from injected muscle showed higher 3 and 7 day retention of CD16+ compared with CD16- monocytes (P&lt;0.05). Five patients with CLI underwent leukapheresis and isolation of CD16+ cells (CliniMACS) under GMP conditions. Autologous cells (30x10 7 ) were radiolabeled with Indium 111 and injected into ischemic legs. Cells were tracked at 30mins, 2, 24 and 72 hours using whole-body γ-camera imaging: radiodecay-corrected retention percentages were 60.0, 37.4, 29.9 and 22.0% respectively with evidence of “washout” into the liver. Analysis of muscle biopsies showed &gt;85% viability of the cells at 10 days and areas of increased arteriogenesis compared with remote, non-injected muscle. Conclusion: CD16+ Mo are preferentially retained within ischemic muscle in experimental HLI. This first in man study shows these cells remain viable in ischemic tissue. Isolation of sufficient numbers of these cells for delivery directly into poorly perfused muscle may provide a more effective cell therapy for CLI patients.
THE HEMOLYTIC STREPTOCOCCI IN RHEUMATISM
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
First clinical study of breast implants launched
Authors: T. Randall
Journal: JAMA (1992)

ON THE FIRST of this month, after three decades of widespread use, the first Stage 2 research protocol designed to ask basic questions about the safety of silicone gel-filled breast implants got under way. The Food and Drug Administration (FDA)-approved protocol, submitted by Mentor Corporation, Santa Barbara, Calif, is open to any woman who has a "medical need" for breast reconstruction and for whom saline-filled implants are considered medically unsatisfactory. This includes the following: Women who need reconstruction after mastectomy or other cancer treatments, or after therapeutic or prophylactic mastectomy for other medical reasons. This category includes cancer patients whose breasts were previously reconstructed with saline implants or autologous tissue techniques with unsatisfactory results. Women who need reconstruction because of severe breast or chest deformity unrelated to breast cancer or previous mastectomy. The deformity can result from congenital or developmental problems, trauma, or medical or surgical complication
Contents
Authors: M Fukushima, M Usami, M Ikeda, Y Nakai, A Taniguchi, T Matsuura, H Suzuki, T Kurose, Y Yamada, Y Seino, Yuval Heled, Yair Shapiro, Yoav Shani, Daniel Moran, Lea Langzam, Varda Barash, Sanford Sampson, Joseph Meyerovitch, Ta Mouse, Tomohito Gohda, Mitsuo Tanimoto, Kenji Shiina, Takamichi Ito, Michimasa Kobayashi, Shinji Hagiwara, Shigeru Kaneko, Yuichiro Makita, Kazuhiko Funabiki, Satoshi Horikoshi, Yasuhiko Tomino, R Jornayvaz, Roxane Selz, Luc Tappy, Gerald Theintz, J Yudkin, I Juhan-Vague, E Hawe, S Humphries, G Di Minno, M Margaglione, E Tremoli, T Kooistra, P Morange, P Lundman, V Mohamed-Ali, A Hamsten
Journal: Metabolism (2004)